Wojciech Leppert

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/7589160/publications.pdf

Version: 2024-02-01

74 papers 1,986 citations

331538 21 h-index 265120 42 g-index

78 all docs 78 docs citations

78 times ranked 2436 citing authors

#	Article	IF	CITATIONS
1	Mechanisms of Chemotherapy-Induced Peripheral Neuropathy. International Journal of Molecular Sciences, 2019, 20, 1451.	1.8	414
2	Tramadol as an analgesic for mild to moderate cancer pain. Pharmacological Reports, 2009, 61, 978-992.	1.5	129
3	Bone Pain in Cancer Patients: Mechanisms and Current Treatment. International Journal of Molecular Sciences, 2019, 20, 6047.	1.8	113
4	Transdermal and Topical Drug Administration in the Treatment of Pain. Molecules, 2018, 23, 681.	1.7	110
5	CYP2D6 in the Metabolism of Opioids for Mild to Moderate Pain. Pharmacology, 2011, 87, 274-285.	0.9	93
6	The role of tramadol in cancer pain treatment—a review. Supportive Care in Cancer, 2005, 13, 5-17.	1.0	91
7	The Role of Corticosteroids in the Treatment of Pain in Cancer Patients. Current Pain and Headache Reports, 2012, 16, 307-313.	1.3	82
8	Emerging therapies for patients with symptoms of opioid-induced bowel dysfunction. Drug Design, Development and Therapy, 2015, 9, 2215.	2.0	59
9	Long-term safety and efficacy of oxycodone/naloxone prolonged-release tablets in patients with moderate-to-severe chronic cancer pain. Supportive Care in Cancer, 2015, 23, 823-830.	1.0	54
10	The role of opioid receptor antagonists in the treatment of opioid-induced constipation: a review. Advances in Therapy, 2010, 27, 714-730.	1.3	48
11	Role of oxycodone and oxycodone/naloxone in cancer pain management. Pharmacological Reports, 2010, 62, 578-591.	1.5	46
12	Pain Management in Patients with Cancer: Focus on Opioid Analgesics. Current Pain and Headache Reports, 2011, 15, 271-279.	1.3	35
13	Identification of the palliative phase in people with dementia: a variety of opinions between healthcare professionals. BMC Palliative Care, 2015, 14, 56.	0.8	35
14	The role of naloxegol in the management of opioid-induced bowel dysfunction. Therapeutic Advances in Gastroenterology, 2016, 9, 736-746.	1.4	35
15	The impact of opioid analgesics on the gastrointestinal tract function and the current management possibilities [Polish version: WpÅ,yw opioidowych Å>rodków przeciwbólowych na czynnoÁ>ć ukÅ,adu pokarmowego oraz aktualne moŹ⁄4liwoÅ>ci postÄ™powania terapeutycznego p. 132]. Wspolczesna Onkologia, 2012. 2. 125-139.	0.7	32
16	Oxycodone/Naloxone in the Management of Patients with Pain and Opioid–Induced Bowel Dysfunction. Current Drug Targets, 2014, 15, 124-135.	1.0	31
17	Oral Prolongedâ€Release Oxycodone/Naloxone for Managing Pain and Opioidâ€Induced Constipation: A Review of the Evidence. Pain Practice, 2018, 18, 647-665.	0.9	31
18	Implementation of improvement strategies in palliative care: an integrative review. Implementation Science, 2015, 10, 103.	2.5	28

#	Article	IF	Citations
19	A Comparison of Attitudes Toward Euthanasia Among Medical Students at Two Polish Universities. Journal of Cancer Education, 2013, 28, 384-391.	0.6	25
20	Lay and professional stakeholder involvement in scoping palliative care issues: Methods used in seven European countries. Palliative Medicine, 2017, 31, 181-192.	1.3	23
21	Polish Brief Pain Inventory for Pain Assessment and Monitoring of Pain Treatment in Patients with Cancer. Journal of Palliative Medicine, 2010, 13, 663-668.	0.6	22
22	A comparison of oral controlled-release morphine and oxycodone with transdermal formulations of buprenorphine and fentanyl in the treatment of severe pain in cancer patients. Drug Design, Development and Therapy, 2017, Volume 11, 2409-2419.	2.0	21
23	Perioperative Immunosuppression and Risk of Cancer Progression: The Impact of Opioids on Pain Management. Pain Research and Management, 2018, 2018, 1-8.	0.7	20
24	Mirogabalinâ€"A Novel Selective Ligand for the α2δ Calcium Channel Subunit. Pharmaceuticals, 2021, 14, 112.	1.7	20
25	Attitudes of Polish Physicians and Medical Students toward Breaking Bad News, Euthanasia and Morphine Administration in Cancer Patients. Journal of Cancer Education, 2013, 28, 603-610.	0.6	19
26	Assessing quality of care for the dying from the bereaved relatives' perspective: Using pre-testing survey methods across seven countries to develop an international outcome measure. Palliative Medicine, 2019, 33, 357-368.	1.3	19
27	The impact of tramadol and dihydrocodeine treatment on quality of life of patients with cancer pain. International Journal of Clinical Practice, 2010, 64, 1681-1687.	0.8	17
28	The Adaptation of the Sheffield Profile for Assessment and Referral for Care (SPARC) to the Polish Clinical Setting for Needs Assessment of Advanced Cancer Patients. Journal of Pain and Symptom Management, 2012, 44, 916-922.	0.6	17
29	Quality of life assessment in advanced cancer patients treated at home, an inpatient unit, and a day care center. OncoTargets and Therapy, 2014, 7, 687.	1.0	16
30	Delivery Systems of Opioid Analgesics for Pain Relief: A Review. Current Pharmaceutical Design, 2013, 19, 7271-7293.	0.9	16
31	Dihydrocodeine as an Opioid Analgesic for the Treatment of Moderate to Severe Chronic Pain. Current Drug Metabolism, 2010, 11, 494-506.	0.7	15
32	Role of intranasal fentanyl in breakthrough pain management in cancer patients. Cancer Management and Research, 0, , 225.	0.9	15
33	Validation of the Polish version of the European Organization for Research and Treatment of Cancer Quality of Life Questionnaire – Core 15 – Palliative Care in patients with advanced cancer. Palliative Medicine, 2013, 27, 470-477.	1.3	15
34	Analgesic Effects of Morphine in Combination with Adjuvant Drugs in Rats. Pharmacology, 2014, 94, 207-213.	0.9	13
35	Opioid-Induced Endocrinopathy in Cancer Patients: An Underestimated Clinical Problem. Advances in Therapy, 2014, 31, 153-167.	1.3	13
36	Good Quality Care for Cancer Patients Dying in Hospitals, but Information Needs Unmet: Bereaved Relatives' Survey within Seven Countries. Oncologist, 2021, 26, e1273-e1284.	1.9	13

#	Article	IF	Citations
37	The role of methadone in opioid rotation—a Polish experience. Supportive Care in Cancer, 2009, 17, 607-612.	1.0	12
38	Tapentadol – A representative of a new class of MOR-NRI analgesics. Pharmacological Reports, 2018, 70, 812-820.	1.5	12
39	Comparison of the Quality of Life of Cancer Patients with Pain Treated with Oral Controlled-Release Morphine and Oxycodone and Transdermal Buprenorphine and Fentanyl. Current Pharmaceutical Design, 2019, 25, 3216-3224.	0.9	12
40	Clinical practice recommendations for quality of life assessment in patients with gynecological cancer. Przeglad Menopauzalny, 2015, 4, 271-282.	0.6	11
41	The role of rapid onset fentanyl products in the management of breakthrough pain in cancer patients. Pharmacological Reports, 2019, 71, 438-442.	1.5	11
42	Quality of Life in Patients With Advanced Lung Cancer Treated at Home and at a Palliative Care Unit. American Journal of Hospice and Palliative Medicine, 2012, 29, 379-387.	0.8	10
43	STAKEHOLDER INVOLVEMENT THROUGHOUT HEALTH TECHNOLOGY ASSESSMENT: AN EXAMPLE FROM PALLIATIVE CARE. International Journal of Technology Assessment in Health Care, 2017, 33, 552-561.	0.2	9
44	Analgesic efficacy and safety of epidural oxycodone in patients undergoing total hip arthroplasty: a pilot study. Journal of Pain Research, 2017, Volume 10, 2303-2309.	0.8	9
45	The role of oxycodone/naloxone in the management of patients with pain and opioid-induced constipation. Expert Opinion on Pharmacotherapy, 2019, 20, 511-522.	0.9	9
46	Reviews The place of oxycodone/naloxone in chronic pain management. Wspolczesna Onkologia, 2013, 2, 128-133.	0.7	8
47	Dihydrocodeine: safety concerns. Expert Review of Clinical Pharmacology, 2016, 9, 9-12.	1.3	8
48	Analgesic efficacy, adverse effects, and safety of oxycodone administered as continuous intravenous infusion in patients after total hip arthroplasty. Journal of Pain Research, 2017, Volume 10, 1027-1032.	0.8	8
49	Analgesic Effects and Assays of Controlled-Release Tramadol and O-Desmethyltramadol in Cancer Patients with Pain. Current Pharmaceutical Biotechnology, 2011, 12, 306-312.	0.9	7
50	Analgesia and serum assays of controlled-release dihydrocodeine and metabolites in cancer patients with pain. Pharmacological Reports, 2012, 64, 84-93.	1.5	6
51	Long-term administration of high doses of transdermal buprenorphine in cancer patients with severe neuropathic pain. OncoTargets and Therapy, 2015, 8, 3621.	1.0	6
52	Impact of Different Illness Perceptions and Emotions Associated with Chronic Back Pain on Anxiety and Depression in Patients Qualified for Surgery. Pain Management Nursing, 2019, 20, 599-603.	0.4	6
53	Analgesic efficacy of sufentanil in dressings after surgical treatment of burn wounds. Burns, 2021, 47, 880-887.	1.1	6
54	New treatment possibilities for opioid-induced bowel dysfunction. Pain, 2013, 154, 1491-1492.	2.0	5

#	Article	IF	Citations
55	Analgesic Effects of Tramadol in Combination with Adjuvant Drugs: An Experimental Study in Rats. Pharmacology, 2013, 91, 7-11.	0.9	5
56	<p>Comparison of analgesia, adverse effects, and quality of life in cancer patients during treatment of procedural pain with intravenous morphine, fentanyl nasal spray, and fentanyl buccal tablets</p> . Cancer Management and Research, 2019, Volume 11, 1587-1600.	0.9	5
57	Role of intranasal fentanyl in breakthrough pain management in cancer patients. Cancer Management and Research, 2010, 2, 225.	0.9	5
58	<p>Rectal enema of bupivacaine in cancer patients with tenesmus pain – case series</p> . Journal of Pain Research, 2019, Volume 12, 1847-1854.	0.8	4
59	Nationwide survey on volunteers' training in hospice and palliative care in Poland. BMJ Supportive and Palliative Care, 2019, 9, e25-e25.	0.8	4
60	Methadone as an additional opioid for a cancer patient with severe neuropathic and bone pain not responsive to other opioids and adjuvant analgesics. Journal of Palliative Care, 2013, 29, 119-21.	0.4	4
61	The role of methadone in cancer pain treatment – Polish experience. Progress in Palliative Care, 2005, 13, 269-276.	0.7	3
62	Rapid Determination of Sufentanil in Human Plasma by UHPLC–QqQ-MS-MS. Journal of Analytical Toxicology, 2020, 45, 605-611.	1.7	3
63	A CONSULTATION GUIDE FOR ASSESSING THE APPLICABILITY OF HEALTH TECHNOLOGIES:A CASE STUDY. International Journal of Technology Assessment in Health Care, 2017, 33, 577-585.	0.2	2
64	Analgesic Efficacy and Safety of Spinal Oxycodone in Total Hip Arthroplasty: A Preliminary Study. Current Medicinal Chemistry, 2022, 29, 3806-3814.	1.2	2
65	Methadone Cardiotoxicity in Pain Management–-An Important Issue for Clinicians. Clinical Medicine Insights Therapeutics, 2010, 2, CMT.S3331.	0.4	1
66	Successful switch from transdermal buprenorphine to oral controlled-release oxycodone in a patient with locally advanced prostate cancer: a and review of the literature. Wspolczesna Onkologia, 2011, 3, 186-189.	0.7	1
67	The use of a high dose of controlled-release oxycodone in a switch from oral morphine: a [Polish version: Zastosowanie wysokiej dawki oksykodonu o kontrolowanym uwalnianiu po zmianie z doustnej morfiny – p 337. Wspolczesna Onkologia, 2011, 5, 333-340.	0.7	1
68	Dyspepsia and Opioid–Induced Bowel Dysfunction: The Role of Opioid Receptor Antagonists. , 0, , .		1
69	A successful Switch From Transdermal Fentanyl to Transdermal Buprenorphine in a Patient with Neuropathic Pain. American Journal of Hospice and Palliative Medicine, 2014, 31, 101-104.	0.8	1
70	Cognitive and emotional representations of pain in cancer patients at an inpatient unit and home palliative care. Current Problems in Cancer, 2019, 43, 100464.	1.0	1
71	Current status of academic palliative medicine in Poland: a nationwide study. BMC Palliative Care, 2022, 21, .	0.8	1
72	The management of neuropathic pain in cancer patients. , 0, , 191-204.		0

#	Article	IF	CITATIONS
73	5â€The international â€~care of the dying evaluation' (CODE) project: using bereaved relatives to assess care for dying cancer patients in europe and south america. , 2019, , .		0
74	Assessment of the quality of life in elderly patients with osteoarthritis during the treatment of chronic pain with transdermal buprenorphine. Acta Poloniae Pharmaceutica, 2021, 78, 573-582.	0.3	0